Biotechnology company Anixa Biosciences Inc (NASDAQ:ANIX) revealed on Monday that it has received a Notice of Allowance from the United States Patent and Trademark Office for a patent covering its ovarian cancer vaccine technology.

The patent includes broad claims on methods that elicit an immune response targeting Anti-Mullerian Hormone Receptor, Type II (AMHR2), a promising target for ovarian cancer prevention and treatment.

Developed in collaboration with Cleveland Clinic and the National Cancer Institute, the vaccine is designed to prevent and treat ovarian cancer, particularly in high-risk populations such as individuals with BRCA mutations or a family history of the disease.

The allowed claims cover methods of administering an immunogenic composition containing a nucleic acid encoding the AMHR2 polypeptide, specifically targeting the extracellular domain of human AMHR2, to generate an AMHR2-specific immune response.

Dr Amit Kumar, chairman and CEO of Anixa Biosciences, stated that this milestone enhances the company's intellectual property portfolio and strengthens its efforts to advance the vaccine programme.